)
Jules SACAZE
Project Lead
2T-Therapeutics
Jules is a PharmD with a background in entrepreneurship. Coming from rare disease pipeline development at Delbert Pharma, he joined ODDIFACT to position the therapeutic pipeline from a pharma business perspective, prioritizing the highest-value regulatory and commercial indications and structuring the most defensible assets into licensing-ready opportunities. A builder at heart, he launches where others analyze: his first industrial partnership, 2T Therapeutics, with Mabion S.A. to develop the first approved CD20 therapy in rare hematology, is the direct proof.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}